SCHEMBL1880902

SCHEMBL1880902

C[Si](C)(C)c1ccccc1[Si](C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.41
TSHR P16473 2/20 0.35
ACHE P22303 2/20 0.35
ALOX12 P18054 2/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
ESR1 P03372 1/20 0.32
ESR2 Q92731 1/20 0.32
CYP2A6 P11509 1/20 0.31
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
CASP3 P42574 1/20 0.31
SENP8 Q96LD8 1/20 0.31
SENP7 Q9BQF6 1/20 0.31
SENP6 Q9GZR1 1/20 0.31
MGAM O43451 1/20 0.31
CYP1A2 P05177 1/20 0.30
CA12 O43570 1/20 0.30
CA1 P00915 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29726936 1.00 IDO1 (0.41) IDO1TSHRACHEALOX12LMNA
SCHEMBL12817202 0.85 IDO1 (0.34) IDO1
SCHEMBL8932025 0.85 ACHE (0.43) IDO1ACHELMNANPC1RAB9A
SCHEMBL31097920 0.83 SMN1; SMN2 (0.37) IDO1TSHRACHELMNAMAPT
SCHEMBL987121 0.81 TSHR (0.50) IDO1TSHRACHEMAPTCYP2A6
SCHEMBL561045 0.81 IDO1 (0.35) IDO1
SCHEMBL13027844 0.81 ALDH1A1 (0.35) IDO1SMN1; SMN2CYP1A2CA12CA1
SCHEMBL30676960 0.81 ALDH1A1 (0.35) IDO1SMN1; SMN2CYP1A2CA12CA1
SCHEMBL9859144 0.78 IDO1 (0.34) IDO1
SCHEMBL560966 0.78 CA1 (0.43) IDO1CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360549-A1 LOW-TEMPERATURE DEPOSITION PROCESSES TO FORM MOLYBDENUM-BASED MATERIALS WITH IMPROVED RESISTIVITY APPLIED MATERIALS, INC. 2024-10-31 US claimed
WO-2024226669-A1 LOW-TEMPERATURE DEPOSITION PROCESSES TO FORM MOLYBDENUM-BASED MATERIALS WITH IMPROVED RESISTIVITY APPLIED MATERIALS, INC. (US) 2024-10-31 WO claimed
EP-2794548-A1 A CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE Lucite International UK Limited (GB) 2014-10-29 EP claimed
EP-2007703-B1 METAL COMPLEXES FOR USE IN THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS LUCITE INT UK LTD (GB) 2013-12-18 EP claimed
WO-2013093472-A1 A CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE LUCITE INTERNATIONAL UK LIMITED (GB) 2013-06-27 WO claimed
EP-2521616-A1 PROCESS FOR THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS, NOVEL CARBONYLATION LIGANDS AND CATALYST SYSTEMS INCORPORATING SUCH LIGANDS Lucite International UK Limited (GB) 2012-11-14 EP claimed
WO-2011083305-A1 PROCESS FOR THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS, NOVEL CARBONYLATION LIGANDS AND CATALYST SYSTEMS INCORPORATING SUCH LIGANDS LUCITE INTERNATIONAL UK LIMITED (GB) 2011-07-14 WO claimed
CN-101553496-A Novel carbonylation ligands and their use in the carbonylation of ethylenically unsaturated compounds LUCITE INT UK LTD (GB) 2009-10-07 CN claimed
EP-0251408-A1 Novel anti-inflammatory agents, pharmaceutical compositions and methods for reducing inflammation THE PROCTER & GAMBLE COMPANY (US) 1988-01-07 EP claimed
US-12624373-B2 Process for producing anhydrosugar(s) from lignocellulosic biomass UNITED ARAB EMIRATES UNIVERSITY (AE) 2026-05-12 US disclosed
US-20260071244-A1 PROCESS FOR PRODUCING ANHYDROSUGAR(S) FROM LIGNOCELLULOSIC BIOMASS UNIV UNITED ARAB EMIRATES (AE) 2026-03-12 US disclosed
US-20260041097-A1 PLANT PRIMING COMPOSITIONS AND METHODS OF USE THEREOF ZERO GRAVITY SOLUTIONS INC (US) 2026-02-12 US disclosed
US-20250179349-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2025-06-05 US disclosed
US-12262628-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2025-03-25 US disclosed
EP-0337176-B1 Novel benzoic acid derivatives and process for preparing the same SHUDO KOICHI (JP) 1994-12-21 EP disclosed
US-5155249-A Differentiating neoplastic cells, treating psoriasis, immune or inflammatory diseases TAIHO PHARMACEUTICAL CO., LTD. (JP) 1992-10-13 US disclosed
US-5081271-A Differentiation-inducing agent for neoplastic cells; therapeutic agent for psoriasis or immune and inflammatory diseases TAIHO PHARMACEUTICAL CO., LTD. (JP) 1992-01-14 US disclosed
EP-0251408-B1 NOVEL ANTI-INFLAMMATORY AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR REDUCING INFLAMMATION THE PROCTER & GAMBLE COMPANY (US) 1991-04-17 EP disclosed
EP-0337176-A2 Novel benzoic acid derivatives and process for preparing the same Shudo, Koichi, Prof. Dr. (JP) 1989-10-18 EP disclosed
EP-0251408-A1 Novel anti-inflammatory agents, pharmaceutical compositions and methods for reducing inflammation THE PROCTER & GAMBLE COMPANY (US) 1988-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12262628-B2 Organic electroluminescent materials and devices OSBP, OCIAD1, OCIAD2 IDO1 1970/4885TSHR 4153/4885ACHE 881/4885
US-12624373-B2 Process for producing anhydrosugar(s) from lignocellulosic biomass AGL, MGAM, UGGT1 IDO1 1110/4885TSHR 3749/4885ACHE 373/4885
US-20250179349-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OSBP, OCIAD1, OCIAD2 IDO1 1970/4885TSHR 4153/4885ACHE 881/4885
US-20260041097-A1 PLANT PRIMING COMPOSITIONS AND METHODS OF USE THEREOF XBP1, TFEB, AOC1 IDO1 849/4885TSHR 3255/4885ACHE 1605/4885
US-20260071244-A1 PROCESS FOR PRODUCING ANHYDROSUGAR(S) FROM LIGNOCELLULOSIC BIOMASS AGL, MGAM, UGGT1 IDO1 1332/4885TSHR 3887/4885ACHE 456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.